NEOPLASIA : Impact Factor & More
eISSN: 1476-5586pISSN: 1476-5586
Share this on:
Key Metrics
Impact Factor 
< 5
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on NEOPLASIA
NEOPLASIA Journal Specifications
Indexed in the following public directories
Web of Science 
SJR
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in NEOPLASIA ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in NEOPLASIA
Corrigendum to "6-Aminonicotinamide, a G6PD inhibitor, mitigates CAPS1 reduction mediated HCC metastasis via ERK and GSK3β signals" [Neoplasia volume 70 (2025) 101239
- 1 Jan 2026
- Neoplasia (New York, N.Y.)
Post-transcriptional control of HIF-1α by MBNL1 restrains hypoxia-driven stemness in GBM
- 8 Dec 2025
- Neoplasia (New York, N.Y.)
IFNβ−pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6C+myeloid cells
- 3 Dec 2025
- Neoplasia (New York, N.Y.)
Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection
- 3 Dec 2025
- Neoplasia (New York, N.Y.)
Filamin a binds deleted in liver cancer 1 (DLC1) to promote its tumor suppressor activity and inhibit the SRF coactivator MRTF-A
- 28 Nov 2025
- Neoplasia (New York, N.Y.)
OTUD4-ZMYND8-DDX3X Axis Drives Immunosuppressive Microenvironment in Spinal Metastases of Triple-Negative Breast Cancer
- 25 Nov 2025
- Neoplasia (New York, N.Y.)
Corrigendum to "6-Aminonicotinamide, a G6PD inhibitor, mitigates CAPS1 reduction mediated HCC metastasis via ERK and GSK3β signals" [Neoplasia volume 70 (2025) 101239
- 1 Jan 2026
- Neoplasia (New York, N.Y.)
Post-transcriptional control of HIF-1α by MBNL1 restrains hypoxia-driven stemness in GBM
- 8 Dec 2025
- Neoplasia (New York, N.Y.)
IFNβ−pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6C+myeloid cells
- 3 Dec 2025
- Neoplasia (New York, N.Y.)
Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection
- 3 Dec 2025
- Neoplasia (New York, N.Y.)
Filamin a binds deleted in liver cancer 1 (DLC1) to promote its tumor suppressor activity and inhibit the SRF coactivator MRTF-A
- 28 Nov 2025
- Neoplasia (New York, N.Y.)
OTUD4-ZMYND8-DDX3X Axis Drives Immunosuppressive Microenvironment in Spinal Metastases of Triple-Negative Breast Cancer
- 25 Nov 2025
- Neoplasia (New York, N.Y.)
FAQs on NEOPLASIA
How long has NEOPLASIA been actively publishing? 
What is the publishing frequency of NEOPLASIA?
How many articles did NEOPLASIA publish last year?
What is the eISSN & pISSN for NEOPLASIA?
Who is the publisher of NEOPLASIA?
